Human High-Density Lipoprotein (Human HDL) Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 106.52 Bn

Forecast Year, 2035

USD 345.90 Bn

CAGR, 2026 - 2035

12.50%

Report Coverage

Global

What is Human High-Density Lipoprotein (Human HDL) Market Size in 2026?

The global human high-density lipoprotein (Human HDL) market size was calculated at USD 106.52 billion in 2025 and is predicted to increase from USD 119.84 billion in 2026 to approximately USD 345.90 billion by 2035, expanding at a CAGR of 12.50% from 2026 to 2035. The human high-density lipoprotein (human HDL) market is growing rapidly due to the high prevalence of cardiovascular issues, leading to higher demand for treatment options and therapeutics to raise HDL levels. The market is also driven by research into dysfunctional HDL particles.

Key Takeaways

• North America led the global human high-density lipoprotein (human HDL) market with 39.70% market share in 2025.
• Asia Pacific is observed to be the fastest-growing region in the foreseeable period.
• By product type, the native human HDL segment led the global market with a share of 32.60% in 2025.
• By product type, the HDL cholesterol reference materials and calibrators segment is expected to grow at the fastest CAGR of 11.20% in the foreseen period.
• By grade, the research grade segment registered its dominance over the global market with 52.80% share in 2025.
• By grade, the clinical reference material grade segment is expected to expand rapidly in the market with a CAGR of 10.70% in the forecast period.
• By application, the cardiovascular and atherosclerosis segment held the largest revenue share, approximately 34.10%, in 2025.
• By application, the cholesterol efflux and reverse cholesterol transport studies segment is expected to gain the highest share of the market with a CAGR of 11.40% in the coming years.
• By end user, the IVD manufacturers segment dominated the global market with 28.60% human high-density lipoprotein (human HDL) market share in 2025.
• By end user, the pharmaceutical and biotechnology companies segment is observed to have the highest CAGR of approximately 11.10% in the forecast period.
• By sales channel, the direct sales segment contributed the biggest revenue share of of 41.80% in 2025.
• By sales channel, the e-commerce and catalog platforms segment is expected to have the highest CAGR of 10.30% in the coming years.

What is the Human High-Density Lipoprotein (Human HDL) Market?

The human high-density lipoprotein market comprises plasma or serum-derived human HDL materials and related reagents used to support biomedical research, assay development, and diagnostic manufacturing. It includes native HDL, HDL subfractions, ApoA-I, HDL cholesterol reference materials, and HDL quantification kits supplied in research and IVD grades. These products enable studies of lipid transport, cholesterol efflux, inflammation, and cardiometabolic risk, and support calibrators and controls for HDL testing. Revenues include product sales, bulk supply, and associated technical services. The market is also driven by the growing prevalence of cardiovascular diseases, further propelling the demand for effective treatment options to help raise HDL levels in patients.

What is the Role of Technology in the Growth of the Market?

Technology drives human high-density lipoprotein (human HDL) market growth through HDL-based nanotherapeutics, which use engineered particles to deliver drugs directly to diseased tissues. Furthermore, functional diagnostics, such as CEC assays, enhance risk assessment by measuring HDL performance, while therapeutic mimetics offer precise treatments for atherosclerosis and inflammation. Explore the market trends in advanced drug delivery systems for more details.

Human High-Density Lipoprotein (Human HDL) Market Trends

• Market focus is shifting from total HDL volume to particle functionality and size. Research indicates that the quality and efficiency of HDL are more reliable indicators of cardiovascular health than quantity.
• Technological growth is driven by HDL-based nanocarriers. These engineered particles deliver drugs directly to plaques or cancer cells, leveraging their small size to penetrate tissues more effectively than traditional delivery methods.
• There is an increasing demand for functional diagnostics, such as CEC assays. These tools measure how well HDL works, rather than just the amount present, allowing for earlier cardiovascular risk detection.

Market Scope

Segmental Analysis

Product Type Insights

Which Component of the Product Segment Led the Global Market in 2025?

The native human HDL segment held a dominant position in the human high-density lipoprotein (human HDL) market with a share of 32.60% in 2025. The native human HDL is isolated directly from human plasma and is a complex mixture of lipoproteins containing 45-55% protein and 55-45% lipid. The main aim of the segment is focused on preclinical, academic, and industrial research aimed at understanding the anti-inflammatory, antioxidant, and anti-atherosclerotic roles of HDL. The segment also observes major growth due to the growing prevalence of cardiovascular issues, leading to a growing focus on therapeutic angiogenesis.

The HDL cholesterol reference materials and calibrators segment is expected to grow at the fastest CAGR of 11.20% in the market between 2026 and 2035. The segment majorly focuses on ensuring accuracy, precision, and traceability of diagnostic assays used for measuring the HDL-C for diagnosing cardiovascular risk. Accurate HDL-C levels are essential to identify the cardiovascular risk and begin the required treatment immediately. Hence, the segment involves the use of specialized calibrators to calibrate direct and enzymatic methods, using serum-based materials. Such high-quality products derived from human serum to mimic clinical samples are a major market driver in the foreseen period.

Grade Insights

Why did the Research Grade Segment Fuel the Growth of the Market in 2025?

The research grade segment accounted for a considerable revenue share of 52.80% of the human high-density lipoprotein (human HDL) market in 2025. The segment's growth is mainly driven by high demand for research in fields such as cardiovascular, metabolic, and immunology. The main aim of the segment involves analysing the major shift of the market from simple measuring cholesterol levels to investigating the therapeutic, structural, and functional properties of the particle.

The clinical reference material grade segment is expected to grow with the highest CAGR of 10.70% in the market during the studied years. The segment is crucial for calibrating laboratory equipment, validating new diagnostic methods, and ensuring the HDL-C results are consistent across different labs and over time. The key roles of the segment involve standardization of diagnostic assays, traceability in measurements, validation of new diagnostic tools, quality control in labs, and support for research and development.

Application Insights

Which Component of the Application Segment Propelled the Growth of the Market in 2025?

The cardiovascular and atherosclerosis research segment led the global human high-density lipoprotein (human HDL) market with a share of 34.10% in 2025. The segment also signifies the importance of the shift of the industry from HDL quantity to HDL functionality. The atherosclerosis research identified that HDL can become dysfunctional under certain conditions. The segment also signifies the market's shift from just raising the HDL-C levels to developing therapies to restore or improve HDL functionality, such as cholesterol efflux capacity.

The cholesterol efflux and reverse cholesterol transport studies segment is expected to expand rapidly in the market with a CAGR of 11.40% in the coming years. The segment highlights the importance of defining HDL function, moving beyond simple cholesterol quantity to quality, and determining cardioprotective capacity. Such studies are also essential to validate novel therapeutic targets aimed at reducing atherosclerotic plaque by promoting cholesterol removal from vessels to the liver.

End User Insights

Why did the IVD Manufacturers Segment lead the Global Market in 2025?

The IVD manufacturers segment registered its dominance over the human high-density lipoprotein (human HDL) market with 28.60% in 2025. The segment has a major role in the market's growth as it aids in developing, producing, and supplying the assays, reagents, and instruments to measure the ‘good' cholesterol levels. Such instruments are technologically advanced and hence help in easily assessing cardiovascular risk in the form of automated, direct, and precise testing. The companies related to the industry produce, sell, and maintain high-speed analyzers to handle high volumes of lipid profile tests and improve lab throughput.

The pharmaceutical and biotechnology companies segment is expected to witness the fastest growth in the market with a CAGR of approximately 11.10% in the forecast period. The segment has a major role in the growth of the market, as such companies aid the development of therapies helpful to elevate the HDL-C levels and enhance HDL functionality to treat cardiovascular issues effectively. It helps to promote cholesterol efflux and plaque regression. The biotech firms focus on inhibiting cholesteryl ester transfer protein to raise HDL-C levels with various agents under investigation to improve cardiovascular health.

Sales Channel Insights

Which Component of the Sales Channel Segment led the Global Market in 2025?

The direct sales segment held the largest revenue share of 41.80% in the human high-density lipoprotein (human HDL) market in 2025. The segment has a critical role in balancing direct, high-touch support for medical institutions on digital platforms. The segment's growth is also driven by the growing need for reliable, rapid, and accurate assessment of cardiovascular risk globally. The segment signifies the direct relationship of the segment with hospitals, clinics, and diagnostic laboratories, focusing on technical support and training, contract management, and regulatory compliance.

The e-commerce and catalog platforms segment is expected to gain the highest share of the market with a CAGR of 10.30% in the forecast period. The main aim of the segment involves streamlining the procurement of diagnostic kits, reagents, and research-grade proteins. The online platforms also help the market to enhance market accessibility, enable efficient comparison of complex specifications, and facilitate direct-to-consumer or direct-to-lab distribution for research and clinical diagnostics. Such platforms are also highly essential for purchasing HDL cholesterol kits for biochemistry analyzers.

Regional Insights

How Big is the North America Human High-Density Lipoprotein (Human HDL) Market Size?

The North America human high-density lipoprotein (Human HDL) market size is estimated at USD 42.29 billion in 2025 and is projected to reach approximately USD 138.36 billion by 2035, with a 12.58% CAGR from 2026 to 2035.

Why did North America lead the Global Market in 2025?

North America led the global human high-density lipoprotein (human HDL) market in 2025 with 39.70% share. The major factors propelling the growth of the market involve growing rates of cardiovascular issues, sedentary lifestyle, improper food habits, and growing investment in the healthcare domain to keep a track of cholesterol levels. The market in the region also observes growth due to higher demand for lipid analysis devices and diagnostic kits for timely cardiovascular risk assessment. It also leads to growing investment in diagnostic products. Growing R&D in the industry also propels the growth of the market.

What is the Size of the U.S. Human High-Density Lipoprotein (Human HDL) Market?

The U.S. human high-density lipoprotein (Human HDL) market size is calculated at USD 31.72 billion in 2025 and is expected to reach nearly USD 104.46 billion in 2035, accelerating at a strong CAGR of 12.66% between 2026 to 2035.

The U.S. Market Trends Analysis

The U.S. has a major contribution to the growth of the market, mainly due to factors such as research, diagnostics, and increasingly therapeutic applications. Higher demand for clinical trials for novel cardiovascular treatments, such as obicetrapib. Growing demand for high-quality, standardized materials and bulk quantities for IVD manufacturers also propels the market's growth.

Why is the Asia Pacific Observed to be the Fastest Growing Region in the Foreseen Period?

Asia Pacific is observed to have the highest CAGR of human high-density lipoprotein (human HDL) market in the forecast period. The market is observing growth in the region due to rising research into cardiovascular diseases (CVD), metabolic disorders, and the development of HDL-mimetic nanotherapeutics. Growing demand for advanced lipid research tools due to growing metabolic health issues in Asian countries is another major driver of the market in the region. Factors such as cardiovascular research, drug delivery, therapeutic development, and diagnostic markers also have a major role in the industry's growth in the foreseeable period.

China Market Trends Analysis

The growing demand for diagnostic, research, and therapeutic solutions for cardiovascular diseases plays a major role in the growth of the market. The growing prevalence of health disorders such as diabetes, metabolic disorders, and CVD is also a major market driver. China also has a major contribution to the market's growth in the foreseeable period due to the growing need for monitoring lipid profiles to address conditions like hypertriglyceridemia, diabetes, and hepatitis.

Human High-Density Lipoprotein (Human HDL) Market Companies in the Market

• Merck KGaA (Sigma-Aldrich)
• Thermo Fisher Scientific
• Abcam
• Bio-Rad Laboratories
• Abbott
• Roche
• Siemens Healthineers
• Beckman Coulter (Danaher)
• Fujifilm Wako
• Randox
• Sekisui Diagnostics
• Lee Biosolutions
• MP Biomedicals
• Technopath Clinical Diagnostics
• Verichem Laboratories

Recent Developments in the Market

• In November 2025, according to a 2025 American Heart Association presentation, a 15-patient, Phase 1 trial showed that a single-dose CRISPR-Cas9 gene-editing therapy safely and effectively lowered LDL cholesterol and triglycerides in patients with difficult-to-treat lipid disorders. The treatment, targeting the ANGPTL3 gene, demonstrated significant, rapid, and sustained reductions. (Source: https://newsroom.heart.org )
• In October 2025, researchers discovered that high-density lipoprotein (HDL) protects the liver by blocking inflammatory signals from gut bacteria, redefining "good cholesterol" as a key guardian against tissue damage.

Segments Covered in the Report

By Product Type

• Native human HDL (plasma or serum-derived)
• HDL subfractions (HDL2)
• HDL subfractions (HDL3)
• Human apolipoprotein A-I (ApoA-I)
• HDL cholesterol reference materials and calibrators
• Human HDL quantification assay kits

By Grade

• Research grade
• IVD manufacturing grade
• Clinical reference material grade

By Application

• Cardiovascular and atherosclerosis research
• Cholesterol efflux and reverse cholesterol transport studies
• Inflammation and immunometabolism studies
• Metabolic disease research
• IVD controls and calibrators manufacturing

By End User

• Pharmaceutical and biotechnology companies
• Academic and government institutes
• Contract research organizations
• IVD manufacturers
• Clinical and reference laboratories

By Sales Channel

• Direct sales
• Life science distributors
• E-commerce and catalog platforms
• Contract supply and bulk procurement

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa